Y Yuan1, H Ma1, Z Ye1, W Jing2, Z Jiang3. 1. Department of Rheumatology and Immunology, the First Hospital, Jilin University, 130021, Changchun, China. 2. Department of Gerontology, the First Hospital, Jilin University, 130021, Changchun, China. 3. Department of Rheumatology and Immunology, the First Hospital, Jilin University, 130021, Changchun, China. jlujzy@163.com.
Abstract
BACKGROUND: The aim of this study was to (a) assess the relationship between interferon-stimulated gene 15 (ISG15) expression and clinical manifestations of systemic lupus erythematosus (SLE) and (b) investigate the diagnostic value of ISG15 in SLE. PATIENTS AND METHODS: The study comprised 28 patients newly diagnosed with SLE, 10 patients with undifferentiated connective tissue disease, and 22 healthy volunteers. Of the SLE patients, 14 were chosen randomly to be followed up for 4 weeks. ISG15 expression in whole blood cells was determined by quantitative polymerase chain reaction. Clinical and laboratory parameters were recorded at baseline and after treatment. RESULTS: The ISG15 mRNA level was higher in whole blood cell counts of SLE patients when compared with the disease control and healthy control groups. Moreover, it was correlated with SLE disease activity as assessed via the SLE disease activity index, serositis, and anemia at baseline. ISG15 expression correlated with lymphocytopenia in active SLE patients before treatment. On receiver operating characteristic curve analysis, the area under the curve for ISG15 expression was 0.826 (p = 0.000015). CONCLUSION: ISG15 expression is relatively high in SLE patients and correlates with disease activity before treatment. ISG15 expression is higher in SLE patients with lymphocytopenia before treatment.
BACKGROUND: The aim of this study was to (a) assess the relationship between interferon-stimulated gene 15 (ISG15) expression and clinical manifestations of systemic lupus erythematosus (SLE) and (b) investigate the diagnostic value of ISG15 in SLE. PATIENTS AND METHODS: The study comprised 28 patients newly diagnosed with SLE, 10 patients with undifferentiated connective tissue disease, and 22 healthy volunteers. Of the SLEpatients, 14 were chosen randomly to be followed up for 4 weeks. ISG15 expression in whole blood cells was determined by quantitative polymerase chain reaction. Clinical and laboratory parameters were recorded at baseline and after treatment. RESULTS: The ISG15 mRNA level was higher in whole blood cell counts of SLEpatients when compared with the disease control and healthy control groups. Moreover, it was correlated with SLE disease activity as assessed via the SLE disease activity index, serositis, and anemia at baseline. ISG15 expression correlated with lymphocytopenia in active SLEpatients before treatment. On receiver operating characteristic curve analysis, the area under the curve for ISG15 expression was 0.826 (p = 0.000015). CONCLUSION:ISG15 expression is relatively high in SLEpatients and correlates with disease activity before treatment. ISG15 expression is higher in SLEpatients with lymphocytopenia before treatment.
Authors: Matthew A Care; Sophie J Stephenson; Nicholas A Barnes; Im Fan; Alexandre Zougman; Yasser M El-Sherbiny; Edward M Vital; David R Westhead; Reuben M Tooze; Gina M Doody Journal: J Immunol Date: 2016-06-29 Impact factor: 5.422
Authors: Ann Elisabet Østvik; Tarjei Dahl Svendsen; Atle van Beelen Granlund; Berit Doseth; Helene Kolstad Skovdahl; Ingunn Bakke; Silje Thorsvik; Wahida Afroz; Gunnar Andreas Walaas; Tom Eirik Mollnes; Björn Inge Gustafsson; Arne Kristian Sandvik; Torunn Bruland Journal: J Crohns Colitis Date: 2020-07-30 Impact factor: 9.071
Authors: Abby D Benninghoff; Melissa A Bates; Preeti S Chauhan; Kathryn A Wierenga; Kristen N Gilley; Andrij Holian; Jack R Harkema; James J Pestka Journal: Front Immunol Date: 2019-12-13 Impact factor: 7.561
Authors: Elizabeth J Brant; Edward A Rietman; Giannoula Lakka Klement; Marco Cavaglia; Jack A Tuszynski Journal: PLoS One Date: 2020-03-19 Impact factor: 3.240